

MED THERAPY PRO

**improves the tolerance of
chemotherapy¹**

Clinical study on the reduction of chemotherapy-induced side effects through treatment with PMA zeolite¹

Study Design: randomized, double-blind, placebo controlled	Clinical study results¹:
Inclusion Criteria: histologically confirmed cancer diagnosis, ≥ 18 years of age predominantly colorectal carcinoma	<ul style="list-style-type: none"> • Compliance: 21 % less therapy cancellations (p = 0,03)* thanks to PMA zeolite treatment • Hematologic toxicity: 72 % lower incidence of severe toxicity (G2-G3) in the PMA zeolite group (p = 0.09)**
Duration: 3.5 years	<ul style="list-style-type: none"> • CIPN: Significant reduction of CIPN (Chemotherapy Induced Peripheral Neuropathy) by 28 % in the subgroup of men (p = 0.047)***
Number of Patients: 120 adults (thereof 112 Colon carcinoma)	
Dosage: 3 g PMA zeolite orally 2 times a day or placebo during and until 1 month after completion of che- motherapy: Oxaliplatin derivatives (highly neurot- oxic, adjuvant / first line / second line)	First results of the follow-up data²: <ul style="list-style-type: none"> • PFS: Positive trend for PFS for elderly patients > 70 years of age (p = 0.1)**** • OS: In terms of overall survival rate in 1st line patients showed an advantage for the PMA zeolite group, with 29 % lower mortality (p = 0.1)*****
Method & Diagnostics: Measurement of nerve conduction velocity (NCS); Before initiation, after 3 and 6 months; chemotherapy-induced peripheral neuropathy (CIPN), hematologic toxicity, during the chemotherapy cycle	
Scientific Lead: Prof. G. Carteni, Dr. med. M. G. Vitale	<p>* patients with more than eight chemotherapy cycles ** trend to severe toxicity (G2-3) in the placebo-group compared to the PMA zeolite-group (12.1 % vs. 3.4 %) *** there is neither a trend nor significance with women (p=0.43) **** PFS = Progression Free Survival ***** OS = Overall Survival</p>

Molecules, Open Access
Journal by MDPI, listed in
PubMed, Cite-Score: 3.28
(Scopus), Impact
Factor: 3,060

PANACEO MED THERAPY-PRO
**enables better adherence to the
oncology treatment protocol**




MED
THERAPY
PRO

improves the tolerance of chemotherapy¹

71.7 % of the patients receiving cancer therapy were able to complete eight chemotherapy cycles thanks to the additional PMA zeolite treatment (p = 0.03)

21 % less therapy cancellations (compliance improvement) thanks to PMA zeolite treatment compared to placebo intake



Group

- PMA zeolite
- Placebo

(p = 0.03)



- Intake of medication within a time difference of 2 hours.
- Therapy break on the day of radiation therapy.
- If obstipation occurs: immediately reduce the dosage and support the gut mobility with increased water intake as well as other substances.

Strengthens
gut & liver

Further studies confirm that **MED THERAPY-PRO** strengthens the intestines and relieves the liver. It

- reduces diarrhea and flatulence³
- regenerates the intestinal mucosa⁴, alleviates inflammatory processes inside the gut and increases the microbiome⁵
- balances liver values (NIS)⁶
- selectively binds ammonium and toxins* and releases important trace elements in the gastro intestinal tract⁷



1. Vitale, M. G. et al., 2020
 2. Vitale, M. G. et al., Follow-up Studie Neapel, Publikation in Vorbereitung (2021)
 3. Vogelsang in preparation
 4. Lamprecht et al., 2014
 5. Mossgöller et al., 2021
 6. NIS Panaceo
 7. Pavelić et al., 2017
- * lead, cadmium, arsenic, chromium, nickel

Panaceo International GmbH
Finkensteiner Straße 5
9585 Villach/Gödersdorf
T: +43/4257/290 64
F: +43/4257/290 64-799
E: office@panaceo.com

PANACEO
www.panaceo.com

● Your **active** companion!